6.8 Segment overlay — Pharma distributor

Why pharma distribution warrants its own overlay

Pharma distribution in India is a distinct underwriting world from generic SME trading. The borrower’s cash-flow shape, inventory pattern, customer concentration, working-capital cycle, and regulatory exposure all differ enough that standard SME WC rules under-perform — they decline good distributors and approve bad ones — unless overlaid with segment-specific signals.

The characteristics:

• High anchor concentration by design — most distributors carry 4 – 10 major manufacturer brands (“companies”) with the top one often 40 – 70% of turnover. Standard concentration rules would decline these borrowers; pharma rules adjust.
• Stable but tight margins — typically 4 – 8% gross on branded pharma, often less on generics. Volume and turn matter more than per-unit margin.
• Highly seasonal scheme distortions — manufacturers offer end-of-quarter, end-of-year, festival, and product-launch schemes (cash discount, credit-period extension, bonus units, target-linked discounts) that distort short-window GST and bank patterns.
• Receivable from chemists — many small chemists; credit period 15 – 45 days; high churn at the tail; some receivables routinely roll forward.
• Regulatory licences — Drug Licence (Form 20B / 21B), GST registration, FSSAI for some categories. License lapses are decline-worthy events.
• Cold-chain handling for some segments (insulin, vaccines) — fixed-asset intensity and operational complexity.

Standard rules that need adjustment

Standard rule	Default	Pharma overlay
Top buyer concentration	<= 40% for A; <= 60% for B	Not applicable — top “supplier” (manufacturer / anchor) concentration is the relevant signal, with different thresholds
Top supplier concentration	<= 50%	<= 70% is normal for a top brand; treat as positive signal not negative
Receivable ageing	<= 20% over 90 days for A	<= 30% is acceptable given chemist payment patterns; trend matters more than absolute
Inventory turn	>= 6 / year for traders	>= 8 / year is normal for active pharma distributors; lower indicates over-stocking or scheme inventory
Monthly volatility (GST)	<= 50% coefficient of variation for A	Higher tolerance (<= 70%) due to scheme distortions; assess on 12-month rolling rather than month-to-month
Bank credit vs GST sales	within 15% for A	Within 20% acceptable; scheme-driven cash discounts create legitimate divergence

Pharma-specific rules to add

Drug Licence validity

Rule	pharma_drug_licence_valid
Purpose	Without a valid Drug Licence, the borrower cannot legally trade pharma
Data source	Borrower upload + manual or third-party verification with Drug Controller portal of the state
Logic	Licence active, not expired, not suspended
Threshold	Hard
Action	DECLINE on expiry / suspension
Manual review	Renewal in process with evidence; REFER
Audit evidence	Licence document with verification reference

Anchor brand mix

Rule	pharma_anchor_brand_mix
Purpose	A distributor with multiple top-tier manufacturer brands has more resilient cash flow than one dependent on a single mid-tier brand
Data source	Borrower-declared + GST 2A purchases analysed for vendor patterns
Logic	Count of top-tier manufacturers (top 30 – 50 by Indian market share) in last 12 months of purchases
Threshold	>= 3 for A; >= 2 for B; < 2 REFER
Action	Per grade
Manual review	Strong single-anchor with > 10 years distributorship; REFER toward acceptance

Distributorship vintage with anchor

Rule	pharma_distributorship_vintage
Purpose	Long-tenured distributorships indicate anchor’s confidence and operational stability
Data source	Borrower-declared, verifiable from anchor-issued certificates / GST history
Logic	Years of unbroken distributorship with the top-3 anchors
Threshold	>= 5 years for A on top anchor; >= 3 years for B
Action	Contribute to grade

Scheme-credit cycle handling

Rule	pharma_scheme_adjusted_turnover
Purpose	Manufacturer schemes inflate purchases episodically; un-adjusted purchase data over-states demand
Data source	GSTR-2A (inward purchases) + borrower declaration of recent scheme events
Logic	Compute rolling 12-month purchase value smoothed for known scheme months
Threshold	Use smoothed turnover for underwriting, not peak month
Action	Adjusts the GST-turnover scorecard

Chemist concentration (downstream)

Rule	pharma_chemist_concentration
Purpose	Distributors with too few large chemists are vulnerable to single-chemist default
Data source	GSTR-1 (outward supplies) + tally / debtor ageing where available
Logic	Number of unique chemist customers over 12 months
Threshold	>= 100 distinct customers for A; >= 40 for B; < 40 REFER
Action	Per grade

Receivable concentration

Rule	pharma_top_chemist_dependence
Purpose	Even with many customers, a single chemist exceeding 25% of receivables is a red flag
Data source	Tally / accounting ageing OR derived from bank-credit patterns
Logic	Top chemist receivable / total receivable
Threshold	<= 25% for A; <= 40% for B
Action	Per

Cold-chain capability (if relevant)

Rule	pharma_cold_chain_required
Purpose	If the distributor carries cold-chain products, operational maturity matters
Data source	Borrower declaration + photo evidence in field FI
Logic	Cold-chain infrastructure present (refrigerators, temperature monitors, SOP)
Threshold	Mandatory if cold-chain SKU in inventory
Action	REFER on absence with cold-chain SKU

Cash-flow underwriting overlays

For pharma WC, the cash-flow rules differ:

• DSC threshold: >= 1.8× for A (lower than standard 2.5×) because cash conversion is fast and predictable.
• Working-capital cycle: 30 – 60 days typical; cycle > 90 days flags weak chemist collection — REFER.
• Bank balance volatility: Higher than standard SME is normal because manufacturer payments are large and lumpy. Look at 7-day rolling rather than EOD.

Pricing and exposure

For verified pharma distributors with strong anchor relationships:

• Lower pricing band — typically ~50 – 100 bps below standard A-grade SME WC due to lower assessed risk.
• Higher ticket eligibility — strong distributors may qualify for higher limits than standard ticket grid suggests, subject to single-borrower cap.
• Repeat-borrower fast-track — repeat pharma borrowers with 12 months clean performance can be auto-renewed with light review.

Common fraud patterns

Pattern	Detection
Fake purchases (claiming anchor purchases that didn’t happen)	GSTR-2A cross-check with anchor’s known GSTIN
Cycling chemist invoices (selling-buying-returning to inflate turnover)	High return-credit-note volume in GSTR-1
Cold-chain SKU without cold-chain capability (selling counterfeit / spoiled stock)	Field FI; complaints
Drug licence lapse (continuing to trade after expiry)	Periodic re-verification
Diversion of branded stock (selling outside agreed territory)	Anchor channel-management info if shared
Bonus-stock-driven inflated turnover (one-time scheme purchase inflating annual turnover)	Smooth purchase analysis

Data sources to prioritise

• GSTR-2A / 2B for verified anchor purchases.
• Tally for chemist ageing and inventory; strongly recommended for pharma — CA support typically present.
• Field FI with photos of shop, cold-chain (if applicable), stock pattern.
• Drug Licence verification at state Drug Controller portal.
• Manufacturer / anchor reference if relationship permits.

Co-lending implications

Pharma WC loans are typically PSL-eligible if the borrower is MSME-registered (most distributors are Small / Medium). They are attractive co-lending candidates for bank partners:

• PSL eligibility clear (MSME).
• Risk shape predictable.
• Repeat rate high.
• Geographic distribution wide (every city / town has pharma distributors).

Most co-lending partners welcome pharma distributor portfolios. Specific co-lending pools for pharma are common.

Where this overlay sits in the engine

This overlay is a per-segment rule set added to the standard policy. When an application is identified as a pharma distributor (NIC code 46497, 46494, or related Drug categories), the engine:

1. Applies standard rules with adjusted thresholds.
2. Adds the pharma-specific rules above.
3. Applies pharma-specific pricing and exposure grids.

The segment tag is set at application based on the borrower’s primary NIC code and confirmed via GST data and field verification.

Repeat-borrower notes

Pharma distributors are excellent repeat borrowers — predictable cycle, high stickiness with the lender once relationship is built, low marginal acquisition cost via CA / anchor channels. The strategic playbook: build the pharma distributor segment to a high single-digit % of the book by year 2 and use it as a stable “anchor cohort” for portfolio performance.

Sources

• NIC codes for pharma distribution per Ministry of Statistics classification.
• State Drug Controller portals for licence verification (verification process varies by state).
• CDSCO (Central Drugs Standard Control Organization) — cdsco.gov.in — for centralised approvals and references.
• Internal portfolio data and standard SME WC underwriting (see 6. Underwriting).